Cash Advance Payments

Scorpion Therapeutics signs agreement with AstraZeneca to discover, develop and commercialize new cancer treatments against “unpredictable” targets

BOSTON–(COMMERCIAL THREAD) – Scorpion Therapeutics, Inc. (“Scorpion”), a next-generation oncology company pioneering Precision Oncology 2.0, today announced a collaboration with AstraZeneca (LSE / STO / NYSE: AZN) to discover, develop and commercialize precision drugs against hard-to-target cancer proteins, with the potential to transform treatment into oncology. The collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes, including cell growth and survival.

Many transcription factors have long been identified as important targets for new cancer treatments and disease drivers, but have historically been considered “non-drug” using conventional drug discovery approaches.

To overcome the challenges of targeting transcription factors and to reach underserved patient populations, this collaboration will combine Scorpion’s fully integrated discovery platform with AstraZeneca’s leadership in the development and commercialization of precision drugs for cancer treatment.

Axel Hoos, MD, Ph.D., CEO of Scorpion said: “We are delighted to conclude this collaboration with AstraZeneca, whose expertise in drug development and commercialization complements our discovery platform, which leverages cutting-edge advances in cancer biology and medicinal chemistry, including chemical proteomics, structure-based drug design and machine learning. We anticipate that this collaboration will accelerate Scorpion’s efforts to deliver on the promise of Precision Oncology 2.0: transformational therapies optimized for more cancer patients. ”

Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca said: “Unlocking potentially transformative biology is key to delivering the next wave of cancer treatments. Scorpion’s innovative platform is a strong strategic fit as we explore a range of new modalities in our extensive drug discovery toolkit with the promise of disrupting the activity of these highly validated cancer targets.

Under the terms of the collaboration agreement, Scorpion will lead the discovery and certain preclinical activities. AstraZeneca has the exclusive option to license worldwide rights for up to three drug candidates. AstraZeneca would be responsible for development and commercialization activities worldwide after accession, while Scorpion would retain the ability to co-develop and co-promote up to two of these programs in the United States under certain conditions, including understood if AstraZeneca exercises three license options.

Scorpion will receive an upfront cash payment of $ 75 million and is eligible to receive up to an additional $ 1.5 billion in option fees and milestone payments, as well as tiered royalties on net sales. ranging from medium to single digit to low to two digits. . In the event that Scorpion commits to co-develop and co-promote a Nominated Program, Scorpion will share in the costs of operation and be entitled to a pro rata share of the economy in the United States, subject to certain adjustments.

About Scorpion Therapeutics

Scorpion Therapeutics is a pioneering oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of cancer patients, a strategy Scorpion calls Precision Oncology 2.0. Scorpion has built a proprietary and fully integrated platform of the most advanced technologies in cancer biology, medicinal chemistry and data science, which enables it to consistently and rapidly create highly selective small molecule compounds against a spectrum. unprecedented targets. Scorpion leverages its platform to advance a broad portfolio of optimized, proprietary compounds in three target categories: the best molecules targeting validated oncogenic targets; first-in-class molecules for hitherto indrogable targets; and first-in-class molecules for new cancer targets.